Akebia (AKBA) CMO Steven Burke reports 10b5-1 and tax-related share sales

Rhea-AI Filing Summary

Akebia Therapeutics SVP and Chief Medical Officer Steven K. Burke reported routine share sales tied to equity compensation and a pre-set plan. On February 2, 2026, he sold 21,582, 25,375, and 20,701 shares of common stock, each at $1.39 per share.

The filing states one sale was made under a Rule 10b5-1 trading plan adopted on November 17, 2023, and the other two were automatic sales by Akebia to cover tax withholding obligations upon vesting of restricted stock units granted in 2023, 2024, and 2025. After these transactions, Burke directly beneficially owned 948,432 shares of Akebia common stock.

Insider Trade Summary

Net Seller: 67,658 shares ($94,045)

Net Sell 3 txns

Insider Burke Steven Keith

Role SVP, Chief Medical Officer

Sold 67,658 shs ($94K)

Type	Security	Shares	Price	Value
Sale	Common Stock	21,582	$1.39	$30K
Sale	Common Stock	25,375	$1.39	$35K
Sale	Common Stock	20,701	$1.39	$29K

Holdings After Transaction: Common Stock — 994,508 shares (Direct)

Footnotes (1)

1. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burke Steven Keith

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S		21,582(1)(2)	D	$1.39	994,508	D
Common Stock	02/02/2026		S		25,375(1)(3)	D	$1.39	969,133	D
Common Stock	02/02/2026		S		20,701(1)(4)	D	$1.39	948,432	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.

2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.

3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.

4. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

Remarks:

	/s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Akebia Therapeutics (AKBA) report in this Form 4?

Akebia Therapeutics reported that SVP and Chief Medical Officer Steven K. Burke sold multiple blocks of common stock on February 2, 2026, at $1.39 per share, with transactions linked to a Rule 10b5-1 plan and tax withholding from vesting restricted stock units.

How many Akebia (AKBA) shares did Steven K. Burke sell and at what price?

Steven K. Burke sold three blocks of Akebia common stock: 21,582 shares, 25,375 shares, and 20,701 shares. All shares were sold on February 2, 2026 at a reported price of $1.39 per share, according to the Form 4 filing.

Does the Akebia (AKBA) Form 4 indicate these insider sales were pre-planned?

Yes. The Form 4 states that one of the sales was made under a Rule 10b5-1 trading plan adopted by Steven K. Burke on November 17, 2023, indicating it was pre-arranged rather than opportunistic trading based on short-term market movements.

Why were some of Steven K. Burke’s Akebia (AKBA) shares sold automatically?

The filing explains that two of the sales were made automatically by Akebia to cover tax withholding obligations. These were linked to the vesting and settlement of one-third portions of restricted stock units granted in January 2023, January 2024, and January 2025.

How many Akebia (AKBA) shares does Steven K. Burke still own after these transactions?

Following the reported transactions, Steven K. Burke directly beneficially owned 948,432 shares of Akebia common stock. This figure reflects his remaining holdings after the three February 2, 2026 sales disclosed in the Form 4 filing.

What is Steven K. Burke’s role at Akebia Therapeutics (AKBA) according to the filing?

The Form 4 identifies Steven K. Burke as an officer of Akebia Therapeutics, serving as Senior Vice President and Chief Medical Officer. He is not listed as a director or a 10% owner in this particular insider ownership report.